HbA1c measurement

Journal of Clinical Pathology

Volumn 57, Issue 4, 2004, Pages 344-345

  Kilpatrick, E S ^a  

^a HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HEMOGLOBIN F;

DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; EDITORIAL; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; PRIORITY JOURNAL; RELIABILITY; RISK ASSESSMENT; NOTE; PREDICTION AND FORECASTING; REFERENCE VALUE;

HEMOGLOBIN A, GLYCOSYLATED; HUMANS; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES;

EID: 1842559506     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2003.010918     Document Type: Editorial

References (18)

1. Gabbay KH, Hasty K, Breslow JL, et al. Glycasylated hemoglobins and long-term blood glucose control in diabetes mellitus. J Clin Endocrinol Metab 1977;44:859-64.
2. Gonen B, Rubenstein A, Rochman H, et al. Haemoglobin A1: an indicator of the metabolic control of diabetic patients. Lancet 1977;2:734-7.
3. Goldstein DE, Little RR, Wiedmeyer HM, et al. Glycated hemoglobin: methodologies and clinical applications. Clin Chem 1986;32:B64-70.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
6. Stratton IR, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
7. Clinical Guideline G. Management of type 2 diabetes. Management of blood glucose. National Institute for Clinical Excellence N0128, September 2002 (www.nice.org.uk).
8. Clinical practice recommendations 2003. Diabetes Care 2003;26:S106-8.
9. http://www.doh.gov.uk/gmscontract/index.htm.
10. Kilpatrick ES. Problems in the assessment of glycaemic control in diabetes mellitus. Diabetic Med 1997;14:819-31.
11. Paisey RB, Read R, Palmer R, et al. Persistent fetal haemoglobin and falsely high glycosylated haemoglobin levels. BMJ 1984;289:279-80.
12. Marshall SM, Barth JH. Standardization of HbA1c measurements - a consensus statement. Diabetic Med 2000;17:5-6.
13. 1c in human blood. Clin Chem Lab Med 2002;40:78-89.
14. 1c in the Diabetes Control and Complications Trial. Diabetes Care 2002;25:275-8.
15. Kilpatrick ES, Maylor PW, Keevil BG. Intraindividual variation of glycated haemoglobin: implications for diabetes screening and monitoring. Diabetes Care 1998;21:261-264.
16. Camargo JL, Gross JL. Conditions associated with very low values of glycohemoglobin measured by an HPLC method. J Clin Pathol 2004;57:346-9.
17. Weykamp CW, Penders TJ, Siebelder CWM, et al. Interference of carbamylated and acetylated hemoglobins in assays of glycohemoglobin by HPLC, electrophoresis, affinity chromatography, and enzyme immunoassay. Clin Chem 1993;39:138-42.
18. Yudkin JS, Forrest RD, Jackson CA, et al. Unexplained variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia. Diabetologia 1990;33:208-15.